PharmTech Weekly Roundup—August 14, 2026

This week on PharmTech.com, content focused on manufacturing capacity, sustainability commitments, and AI adoption. From new fill-finish platforms, a $2.3 billion Texas campus, and a wave of Nordic biotech dealmaking, here's what stood out.

In news this week, Sentynl and Mereo's option deal for the oral elastase inhibitor alvelestat puts CMC and scale-up planning on the table years ahead of a phase 3 readout, treating manufacturing readiness as a gating factor rather than a downstream afterthought.

Bristol Myers Squibb announced $2.3 billion new manufacturing campus in Houston, which is designed as a modular, multi-modal site that can shift between small molecules, biologics, and antibody-drug conjugates without a full rebuild.

Autumn Conference Season

In conference news, Silvia Forroova of CPHI spoke with PharmTech about why sustainability has become a baseline compliance requirement rather than a competitive edge, and how the new CPHI Sustainability Summit, which debuts this year directly before CPHI Milan in October, is designed to turn plans into concrete, cross-industry actions.

Speaking of CPHI Milan, the 2026 program has been announced. This year’s event adds the two-day Sustainability Summit plus new AI, cold chain, and labeling zones to an agenda topped by more than 260 speakers.

Expert Insights

Expert analysis this week includes Jordan Xu’s break down of how pen injector pre-assembly lines hit 160-pens-per-minute precision only by pairing LVDT and machine-vision networks with GAMP5 challenge-parts testing to catch dimensional variability before it becomes a dosing failure.

When it comes to AI in pharma, Open Biopharma's Richard Jaenisch explained that the real AI risk in manufacturing isn't generative drug discovery but coding agents quietly modifying equipment software with permissions nobody is really watching.

And Brian Drapeau, founder of GxPFrame, argued that pharma's disappointing AI ROI isn't a strategy or technology failure but a workforce qualification gap, the same rigor the industry already applies to equipment and assays, pointing to an April FDA warning letter as proof of what happens when it's skipped.

Capacity was also a hot topic this week. Halo Pharma's Glenn Herring detailed the tradeoffs of retrofitting an existing space for the CDMO's new sterile fill-finish suite, where the isolator functions as its own independently air-supplied "factory within a factory."

In addition, Halo Pharma’s CEO Lee Karras tied its new sterile fill-finish manufacturing platform's launch to a domestic injectable supply chain already running at capacity, framing the Apotex anchor deal as the trigger for the site's first FDA inspection.

European Frontrunners

Finally, Cheryl Barton mapped why Danish biotechs are pulling outsized venture and pharma dealmaking interest, with VC investment in the country's life sciences sector nearly tripling since 2018.

This week, it’s clear the industry is investing in capacity, sterile manufacturing, and AI adoption. For the full stories, visit PharmTech.com.